Perspective Therapeutics’ (CATX) Outperform Rating Reaffirmed at Wedbush

Wedbush reiterated their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a research note published on Thursday morning,RTT News reports. They currently have a $11.00 price objective on the stock, down from their prior price objective of $20.00.

Several other equities research analysts also recently issued reports on CATX. Oppenheimer restated an “outperform” rating and set a $22.00 price objective on shares of Perspective Therapeutics in a report on Friday, October 11th. Royal Bank of Canada dropped their price objective on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a report on Friday, August 16th. Truist Financial initiated coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They set a “buy” rating and a $21.00 price objective on the stock. UBS Group initiated coverage on Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective on the stock. Finally, Bank of America assumed coverage on Perspective Therapeutics in a report on Thursday, July 25th. They set a “buy” rating and a $24.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, Perspective Therapeutics currently has an average rating of “Buy” and a consensus target price of $20.29.

Perspective Therapeutics Trading Down 51.2 %

NYSE CATX opened at $3.01 on Thursday. Perspective Therapeutics has a 1-year low of $2.28 and a 1-year high of $19.05. The company has a 50-day moving average price of $11.75.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). The firm had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. Sell-side analysts expect that Perspective Therapeutics will post -0.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC bought a new position in Perspective Therapeutics during the 3rd quarter worth $57,000. US Bancorp DE boosted its position in Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after acquiring an additional 3,866 shares during the period. Intech Investment Management LLC acquired a new position in Perspective Therapeutics during the 3rd quarter worth $137,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Perspective Therapeutics during the 3rd quarter worth $152,000. Finally, Los Angeles Capital Management LLC acquired a new position in Perspective Therapeutics during the 3rd quarter worth $153,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.